Informations générales (source: ClinicalTrials.gov)
Impact of a Systematic Palliative Care on Quality of Life, in Advanced Idiopathic Pulmonary Fibrosis (IPF). A Randomized Multi-center Trial. (PALIF)
Interventional
N/A
Assistance Publique - Hôpitaux de Paris (Voir sur ClinicalTrials)
décembre 2017
février 2021
29 juin 2024
Idiopathic pulmonary fibrosis (IPF) is a rare and severe disease with a survival median
between 2 and 4 years which leads to a profound alteration of the quality of life.
In thoracic oncology, the systematic and early intervention of a palliative care team
result in an improvement of quality of life for patients.
In the princeps study published in 2010, the early intervention of a dedicated palliative
care team was compared to standard care in a randomized trial of 150 patients and shows a
significant improvement : (i) of quality of life (main objective), (ii) of depression
scores and even overall survival (11.6 months vs. 8.9 months, P = 0.02), (iii) a benefit
in terms of understanding the diagnosis and therapeutic goals (3), (iv) diminution of
adapted hospitalization in end of life (in emergency or not).
Considering some analogy points between IPF and advanced lung cancer (prognosis,
respiratory symptom, psychological burden), it seemed reasonable to assume that the joint
systematic intervention of chest physician and palliative care team may provide a
significant benefit in terms of quality of life for patients with severe IPF.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| AP-HP - Hôpital Avicenne | DUCHEMANN Boris | 18/04/2025 07:56:11 | Contacter | ||
| AP-HP - Hôpital Bichat | DUCHEMANN Boris | 18/04/2025 07:56:11 | Contacter | ||
| AP-HP - Hôpital Europeen Georges Pompidou | DUCHEMANN Boris | 18/04/2025 07:56:11 | Contacter | ||
| AP-HP - Hôpital Tenon | DUCHEMANN Boris | 18/04/2025 07:56:11 | Contacter | ||
| CH DE VERSAILLES SITE ANDRE MIGNOT | DUCHEMANN Boris | 12/02/2024 13:48:37 | Contacter | ||
| HOPITAL FOCH | ALEXANDRE CHABROL | 28/04/2025 15:59:47 | Contacter | ||
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| C.H. ROBERT BALLANGER | Jérome VIRALLY, Pr | Contact (sur clinicalTrials) | |||
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Hôpital LARREY - 31059 - Toulouse - France | Grégoire PREVOT, Dr | Contact (sur clinicalTrials) | |||
| Hôpital LOUIS PRADEL - 69677 - Lyon - France | Vicent COTTIN, Pr | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Hôpital DELAFONTAINE - 93200 - Saint-Denis - France | Isabelle LERAT, Dr | Contact (sur clinicalTrials) | |||
| Hôpital Pontchaillou - 35033 - Rennes - France | Stéphane JOUNEAU, Pr | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Age> 40 years
- Patient with confirmed diagnosis of IPF according to the American Thoracic Society
(ATS) / European Respiratory Society (ERS) / Japanese Respiratory Society (JRS) /
Latin American Thoracic Association (ALAT) criteria. The patient may be included
regardless of the date of diagnosis.
- Advanced IPF with Forced Vital Capacity (FVC) <50%" of predicted value and / or
Diffusing capacity for carbon monoxide ((DLCO) <30% of predicted value or inability
to achieve the Functional Respiratory Investigations (EFR) due to respiratory
severity. EFR dated less than 3 months.
- Absence of argument for acute or subacute exacerbation in the last 6 months.
- Patient who can be followed in ambulatory consultation/ outpatient consultation.
- Informed consent signed (signed by the patient or in the presence of a third party
for patients who are poorly fluent in French).
- Affiliation to the social security system.
- Age> 40 years
- Patient with confirmed diagnosis of IPF according to the American Thoracic Society
(ATS) / European Respiratory Society (ERS) / Japanese Respiratory Society (JRS) /
Latin American Thoracic Association (ALAT) criteria. The patient may be included
regardless of the date of diagnosis.
- Advanced IPF with Forced Vital Capacity (FVC) <50%" of predicted value and / or
Diffusing capacity for carbon monoxide ((DLCO) <30% of predicted value or inability
to achieve the Functional Respiratory Investigations (EFR) due to respiratory
severity. EFR dated less than 3 months.
- Absence of argument for acute or subacute exacerbation in the last 6 months.
- Patient who can be followed in ambulatory consultation/ outpatient consultation.
- Informed consent signed (signed by the patient or in the presence of a third party
for patients who are poorly fluent in French).
- Affiliation to the social security system.
- Patient unable to respond to quality of life questionnaires.
- Inability (physical or mental) to give a written informed consent.
- Acute exacerbation of fibrosis in the previous 6 months.
- Patient eligible for a pulmonary transplant.
- Participation in other therapeutic trial
- Patient cannot be followed in ambulatory consultation.
- Patient under trustee